No Data
No Data
Sanbo Neuroscience (301293.SZ): Repurchased 0.54% of shares accumulated.
Sanbo Brain(301293.SZ) announced on August 1st that as of July 31, 2024, the company has repurchased a total of 1,104,600 shares of the company through centralized bidding trading, accounting for 0.54% of the total share capital of the company. The highest fill price was 35.06 yuan/share, the lowest fill price was 34.39 yuan/share, and the total transaction amount was 38,489,000.80 yuan (excluding transaction fees).
Retail Investors Who Hold 53% of Sanbo Hospital Management Group Limited (SZSE:301293) Gained 5.6%, Insiders Profited as Well
Sanbo Neurology (301293.SZ): for the first time repurchased 0.1642 million shares involving 5.6972 million yuan.
On July 19th, Gelonghui reported that Sanbo Brain (301293.SZ) announced that on July 18, 2024, they repurchased 164,160 shares of the company through a repurchase dedicated security account, accounting for 0.08/% of the total share capital of the company, with the highest transaction price of 34.80 yuan/share, the lowest transaction price of 34.46 yuan/share, and a total transaction amount of 5.6972 million yuan (excluding transaction fees) in a centralized bidding manner.
Sanbo Neurology (301293.SZ) is a medical service group specializing in neurological care.
Sanbo Brain Science (301293.SZ) stated on the investor interaction platform on July 18th that it is a medical service group with a focus on neurology. It currently operates seven hospitals, including five specialized in neurology and two comprehensive hospitals. The main diagnosis and treatment projects of the hospital include neurosurgery, neurological intervention, neurology, chemotherapy/radiotherapy for neurotumors, neurocritical care, obstetrics and gynecology, pediatrics, etc.
Sanbo Neurology (301293.SZ) plans to acquire 70% equity of Sichuan Guangze Medical Investment Management.
On July 11th, Guolonghui reported that Sanbo Brain Hospital Management Group Co., Ltd. intends to further integrate resources, businesses, and supply chains in the southwestern regional market. On July 10th, 2024, the company signed an Equity Acquisition Intention Letter with Sichuan Dahang Guangze Medical Investment Management Co., Ltd. (referred to as the 'target company') and its shareholders Zhang Pingzhong, Cao Deli, Xiao Jing, and Zhou Qin to acquire 70% of the equity of the target company in cash.
Sanbo Neurology (301293.SZ): No involvement in the assisted reproduction business at this time.
On July 8th, Gelonhui reported that Sanbo Neurology (301293.SZ) stated on the investor interactive platform that its subsidiary, Luoyang Sanbo, mainly focuses on obstetrics, gynecology, and pediatrics, and does not currently involve assisted reproduction business.
No Data